(0.12%) 5 303.27 points
(0.34%) 40 004 points
(-0.07%) 16 686 points
(0.97%) $80.00
(5.73%) $2.64
(1.44%) $2 419.80
(6.36%) $31.78
(2.18%) $1 094.70
(-0.02%) $0.920
(-0.18%) $10.68
(-0.27%) $0.787
(0.19%) $91.05
Live Chart Being Loaded With Signals
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer...
Stats | |
---|---|
Šios dienos apimtis | 375.00 |
Vidutinė apimtis | 23 677.00 |
Rinkos kapitalizacija | 91.54M |
EPS | $0 ( 2024-05-10 ) |
Kita pelno data | ( $-0.500 ) 2024-08-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 0 |
ATR14 | $0.0310 (1.32%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-10 | Dawes Karen A | Buy | 19 516 | Share Option (Right to Buy) |
2024-05-10 | Scheeren Joseph | Buy | 19 516 | Share Option (Right to Buy) |
2024-05-10 | Phillips Anne M. | Buy | 19 516 | Share Option (Right to Buy) |
2024-05-10 | Hammacher Alex | Buy | 19 516 | Share Option (Right to Buy) |
2024-05-10 | Morgon Pierre A. | Buy | 19 516 | Share Option (Right to Buy) |
INSIDER POWER |
---|
100.00 |
Last 6 transactions |
Buy: 117 096 | Sell: 0 |
Barinthus Biotherapeutics Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Barinthus Biotherapeutics Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $805 108 |
Bruto pelnas: | $802 000 (99.61 %) |
EPS: | $-1.920 |
FY | 2023 |
Pajamos: | $805 108 |
Bruto pelnas: | $802 000 (99.61 %) |
EPS: | $-1.920 |
FY | 2022 |
Pajamos: | $44.70M |
Bruto pelnas: | $44.70M (100.00 %) |
EPS: | $0.140 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Barinthus Biotherapeutics
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.